Vertex Pharmaceuticals (VRTX) Akcija Kursas
Vertex Pharmaceuticals Kursas
Per pastaruosius 19 metus Vertex Pharmaceuticals pajamos augo 23,6 % kasmet ir pasiekė 12,07 mlrd. USD. Pelnas akcijai augo 40,3 % per metus per pastaruosius 14 metus. Vertex Pharmaceuticals grynoji marža 32,7 % yra išaugo palyginti su 30,9 % prieš kelerius metus. Vertex Pharmaceuticals 12 mėn. konsensuso tikslinė kaina yra 580,00 USD, apie virš kursą 6,0 %. Iš 39 analitikų 32 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Vertex Pharmaceuticals akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Vertex Pharmaceuticals akcija ir akcijų analizė
Dažnai užduodami klausimai apie Vertex Pharmaceuticals akciją
The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.
Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.
Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.
Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.
Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.
Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.
Analitikai šiuo metu nustato vidutinę Vertex Pharmaceuticals akcijos tikslinę kainą 553,08 USD (mediana: 580,00 USD), t. y. +1,1 % palyginti su paskutine kaina. Konsensusas pagrįstas 39 analitikų reitingais.
39 analitikai šiuo metu vertina Vertex Pharmaceuticals akciją: 32 rekomenduoja pirkti, 6 laikyti ir 1 parduoti. 2026 m. analitikai tikisi, kad Vertex Pharmaceuticals gaus 13,25 mlrd. USD pajamų ir 18,06 USD pelno akcijai.
Pagal dabartinį kursą Vertex Pharmaceuticals akcija kainuoja 490,25 EUR (547,09 USD).
Vertex Pharmaceuticals akcija (VRTX) kotiruojama 11 biržose, įskaitant: NASDAQ (VRTX), London (0QZU.L), SIX (Zürich) (VRTX.SW), XETRA (VX1.DE), Frankfurt (VX1.F), München (VX1.MU), Düsseldorf (VX1.DU), Hamburg (VX1.HM).
Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.
tikėtina pelnas Vertex Pharmaceuticals yra 13,25 mlrd. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Vertex Pharmaceuticals yra 4,63 mlrd. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Vertex Pharmaceuticals šiuo metu yra 30,29. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Vertex Pharmaceuticals akcijos vertę.
Kainų ir pardavimų santykis (KUV) Vertex Pharmaceuticals šiuo metu yra 10,57. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Vertex Pharmaceuticals akcijos įvertinimo metrika.
Eulerpool kokybės balas Vertex Pharmaceuticals yra 6/10.
Vertex Pharmaceuticals ISIN yra US92532F1003. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Vertex Pharmaceuticals WKN yra 882807. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Vertex Pharmaceuticals prekybos žymė yra VRTX. Ši biržos žymė naudojama Vertex Pharmaceuticals akcijoms prekiauti biržoje.
Vertex Pharmaceuticals akcija
Vertex Pharmaceuticals Pagrindiniai konkurentai
Vertex Pharmaceuticals Biržos simbolis
Vertex Pharmaceuticals FIGI
Visos Vertex Pharmaceuticals pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Vertex Pharmaceuticals akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Vertex Pharmaceuticals. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: